RxDoctor Payments DataLook up a doctor →

Grant Bailey, MD

Cardiovascular Disease · Littleton, CONPI 1881919660

Payments from drug & device makers

$176,562in general payments, 2019–2025

Across 803 payments — averaging $219.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$89K
  • Boehringer Ingelheim$31K
  • Amarin Pharma, Inc.$18K
  • Lilly USA, LLC$11K
  • E.r. Squibb & Sons, L.L.C.$5K
  • Edwards Lifesciences$4K
  • plus $19K from 38 others
$11,926in research payments, 2019–2025

Across 4 payments — averaging $2981.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$12K

What the payments were for

  • Consulting fees$7,4158%
  • Speaking & faculty fees$55,46063%
  • Travel & lodging$4,1275%
  • Food & beverage$20,84124%
  • Education$1530%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$176,562 in reported general payments places this provider in the 95th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$333,716
Medicare patients
1,437
Services billed
3,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban415$528,557
VyndamaxTafamidis14$362,694
CamzyosMavacamten43$343,023
Repatha SureclickEvolocumab197$235,488
JardianceEmpagliflozin149$215,853
XareltoRivaroxaban155$203,150
FarxigaDapagliflozin Propanediol123$159,038
EntrestoSacubitril/Valsartan69$119,110
Praluent PenAlirocumab43$48,862
VascepaIcosapent Ethyl31$24,114
Rosuvastatin Calcium934$13,071
Nebivolol Hcl180$12,429
LivaloPitavastatin Calcium12$9,123
Metoprolol Succinate579$7,462
Ezetimibe351$6,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$828$891,251429 claims
E.r. Squibb & Sons, L.L.C.Camzyos$4,916$343,02343 claims
Boehringer IngelheimJardiance$31,034$215,853149 claims
Johnson & JohnsonXarelto$459$203,150155 claims
AstraZenecaFarxiga$870$159,038123 claims
NovartisEntresto$1,381$119,11069 claims
Kowa Pharmaceuticals America, Inc.Livalo$156$9,12312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 276 cardiovascular disease providers in Colorado.

Other cardiovascular disease in Littleton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →